Radiotracer fluciclovine (18F) PET leads to improved cancer control in recurrent prostate cancer
October 27th 2020EMPIRE-1 is the first randomized trial to demonstrate an improvement in failure-free survival with treatment based on advanced molecular imaging versus conventional imaging in men with recurrent prostate cancer.